5-bromo-6-chloro-N-(2-hydroxypyridin-3-yl)pyridine-3-sulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-bromo-6-chloro-N-(2-hydroxypyridin-3-yl)pyridine-3-sulfonamide
• 英文别名: 5-bromo-6-chloro-N-(2-oxo-1H-pyridin-3-yl)pyridine-3-sulfonamide
• 化学式: C₁₀H₇BrClN₃O₃S
• 分子量: 364.607
• InChiKey: BJSJLCJKIZKJGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-溴-2-氯吡啶-5-磺酰氯 、 3-氨基-2-羟基吡啶 以 甲醇 为溶剂， 反应 2.0h， 以17%的产率得到5-bromo-6-chloro-N-(2-hydroxypyridin-3-yl)pyridine-3-sulfonamide
  参考文献：
  名称：

  [EN] N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS
  [FR] DÉRIVÉS DE N-(HÉTÉROARYL)-SULFONAMIDE UTILES COMME INHIBITEURS DE S100

  摘要：

  化合物的化学式（I），或其药学上可接受的盐以及包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴（如RAGE、TLR4和EMMPRIN）之间相互作用的抑制剂，因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病方面具有用处。

  公开号：

  WO2014184234A1

文献信息

• N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS
  申请人：Active Biotech AB

  公开号：US20160115158A1

  公开（公告）日：2016-04-28

  A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

  化合物(I)的配方，或其药学上可接受的盐和包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴如RAGE、TLR4和EMMPRIN之间相互作用的抑制剂，因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病中有用。
• N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors
  申请人：Active Biotech AB

  公开号：US10125125B2

  公开（公告）日：2018-11-13

  A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

  一种式 (I) 的化合物或其药学上可接受的盐以及包含该化合物的药物组合物。该化合物是 SI 00A9 与 RAGE、TLR4 和 EMMPRIN 等相互作用伙伴之间相互作用的抑制剂，因此可用于治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病。
• US9873687B2
  申请人：——

  公开号：US9873687B2

  公开（公告）日：2018-01-23
• [EN] COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM<br/>[FR] COMPOSÉ POUR LE TRAITEMENT D'UNE INFLAMMATION AIGUË DANS LE MYOCARDE
  申请人：CALPROTECT AB

  公开号：WO2020260692A1

  公开（公告）日：2020-12-30

  The present invention relates to a compound for treatment of a disease or disorder involving inflammation in the myocardium, such as for example myocardial infarction due to myocardial ischemia, myocardial infarction due to myocardial ischemia/reperfusion, myocarditis, sepsis, sepsis-induced myocardial inflammation, and septic cardiomyopathy. The present invention further relates to treatment of a disease or disorder involving inflammation in the myocardium by administration of said compound during the acute phase of said disease or disorder.
• [EN] N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS<br/>[FR] DÉRIVÉS DE N-(HÉTÉROARYL)-SULFONAMIDE UTILES COMME INHIBITEURS DE S100
  申请人：ACTIVE BIOTECH AB

  公开号：WO2014184234A1

  公开（公告）日：2014-11-20

  A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

  化合物的化学式（I），或其药学上可接受的盐以及包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴（如RAGE、TLR4和EMMPRIN）之间相互作用的抑制剂，因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病方面具有用处。